Please read Dr. Kipen’s article in RSC Advances titled, “Detection of respiratory inflammation biomarkers in non-processed exhaled breath condensate samples using reduced graphene oxide.”
Effective diagnosis and treatment of disease relies on accurate molecular tools that reflect a patient’s clinical status. Development of new biomarkers and translating them into useful clinical tools requires novel applications of technology allowing point of care implementation. Monitoring changes in airway inflammation in conditions such as asthma and obstructive pulmonary disease (COPD) can be useful for monitoring disease status and response to therapy. Exhaled breath condensate (EBC) is a matrix that is full of valuable biomolecular information. It is an attractive and non-invasive way to collect soluble components from the lower airways in the respiratory system. The correlation between exhaled breath condensate (EBC) biomarkers and pulmonary inflammation has been widely reported. Also, EBC is a promising alternative method to sampling of the inner lining of the respiratory airway compared to invasive methods to screen and early detection of diseases such as lung cancer. To read the full article.
Detection of respiratory inflammation biomarkers in non-processed exhaled breath condensate samples using reduced graphene oxide. Azam Gholizadeh, Kathleen Black, Howard Kipen, Robert Laumbach, Andrew Gow, Clifford Weisel, and Mehdi Javanmard. RSC Adv. 2022 Dec 12; 12(55): 35627–35638. Published online 2022 Dec 13. PMID: 36545081 PMCID: PMC9745889 DOI: 10.1039/d2ra05764f